Sensipar: profile and news

NPS Elects N. Anthony Coles, MD Chief Executive Officer  May 12, 2006
...its gratitude to Hunter Jackson, the company's co-founder, for his 20 years of leadership and for shepherding two important new medicines, Sensipar(R) and ... - Boursorama,

ConjuChem Announces New Executive Vice President, Research and ...  May 11, 2006
Ulich served in a pivotal leadership role for the regulatory filings of such highly successful drugs as Aranesp, Neulasta, Kepivance, Sensipar, and Denosumab. ... - Canada NewsWire (press release),

Amgen's First Quarter 2006 Adjusted Earnings Per Share, Excluding ...  Apr 18, 2006
Worldwide sales of Sensipar(R) (cinacalcet HCl) increased 126 percent to $61 million in the first quarter of 2006 versus $27 million during the first quarter ... - Genetic Engineering News,

Genzyme's First-Quarter Sales Below Expectations  Apr 19, 2006
This was primarily due to lower than expected Enbrel and Neulasta sales; however, product sales across the board, with the exception of Sensipar, were slightly ... - BioWorld Online (subscription),

Mixed reaction on Amgen spike  Apr 20, 2006
...$896 million. Enbrel sales rose 11 percent to $658 million and global sales of Sensipar jumped 126 percent to $61 million. Ed Nash ... - Monsters and Critics.com,